A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4
Sponsor: Prelude Therapeutics
Terminated
Sponsor decision
Other terminated trials from Prelude Therapeutics
Listed as NCT06560645, this PHASE1 trial focuses on Advanced Solid Tumor and Esophageal Adenocarcinoma and remains terminated or withdrawn. Sponsored by Prelude Therapeutics, it has been updated 13 times since 2024, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Dec 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE1
-
Sep 2025 — Nov 2025 [monthly]
Recruiting PHASE1
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE1
▶ Show 8 earlier versions
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE1
-
May 2025 — Jul 2025 [monthly]
Recruiting PHASE1
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE1
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE1
-
Jan 2025 — Mar 2025 [monthly]
Recruiting PHASE1
-
Dec 2024 — Jan 2025 [monthly]
Recruiting PHASE1
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Nov 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Prelude Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .